Eccrine Systems has raised $1.5 million in seed funding to develop a sweat sensor based on know-how that originated at the University of Cincinnati and the Air Force Research Labs. The Cincinnati, Ohio-based startup will use the cash to forge ahead with the development of wearable sensor technology it plans to pitch to clinical trial sponsors.
Novo Nordisk has set the terms for the IPO of its IT services unit NNIT. If NNIT prices at the top end of its range when it goes public in the next week or so, the listing could generate up to $335 million for Novo Nordisk.
Months after a bitter exit from the top spot at Sanofi, Christopher Viehbacher is back out in public, joining Boston startup factory PureTech to help steer its portfolio of fledgling companies.
South San Francisco's Lyric Pharmaceuticals raised $20.4 million in first-round financing to support its work on a hush-hush gastrointestinal drug.
If anyone had doubts about exactly where Neil Woodford was going to aim the brunt of his new £200 million ($300 million) fund, details of the board that will oversee the venture will have washed away the uncertainty.
Texas-based Neos Therapeutics has rounded up $20.6 million to bankroll their late-stage regulatory work on extended-release formulations of a slate of ADHD drugs that is now being served up to regulators for review.
Bessemer Venture Partners is rolling out a global fund with $1.6 billion to invest in a range of new technologies--including biotech.
Robot-run lab startup Transcriptic has raised $8.5 million in a Series A round to buy more equipment and expand its service offering. The round once again attracted a clutch of big name, Big Data-focused Silicon Valley VC funds, including Data Collective and IA Ventures.
Strong interest from individuals in France has helped Quantum Genomics blast past its IPO targets. The open-price offering was almost 15 times oversubscribed as individuals flocked to the biotech to finance the advance of its blood pressure drug into clinical proof-of-concept trials.
Pennsylvania's Merganser Biotech raised a $28 million A round with the help of Novartis Venture Fund, paying the company's way as it homes in on iron-related diseases.